MXPA04001212A - Derivados de acido hidroxamico. - Google Patents

Derivados de acido hidroxamico.

Info

Publication number
MXPA04001212A
MXPA04001212A MXPA04001212A MXPA04001212A MXPA04001212A MX PA04001212 A MXPA04001212 A MX PA04001212A MX PA04001212 A MXPA04001212 A MX PA04001212A MX PA04001212 A MXPA04001212 A MX PA04001212A MX PA04001212 A MXPA04001212 A MX PA04001212A
Authority
MX
Mexico
Prior art keywords
acid derivatives
hydroxamic acid
cfh2
cf2h
compounds
Prior art date
Application number
MXPA04001212A
Other languages
English (en)
Inventor
Joan Dyke Hazel
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of MXPA04001212A publication Critical patent/MXPA04001212A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de formula (I) en donde: R1 y R2, los cuales pueden ser iguales o diferentes, cada uno es un atomo de hidrogeno o un grupo CF3, CF2H o CFH2, con la condicion de que cuando uno de R1 o R2 es un atomo de hidrogeno el otro es un grupo CF3, CF2H o CFH2; y sus sales, solvatos o hidratos. Los compuestos son inhibidores potentes de la MMP que ventajosamente no provocan tendonitis en un modelo animal relevante. Los compuestos pueden suponerse que con de uso en la medicina, especialmente cuando se desea la prevencion de efectos secundarios como dolor articular.
MXPA04001212A 2001-08-09 2002-08-07 Derivados de acido hidroxamico. MXPA04001212A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0119396.0A GB0119396D0 (en) 2001-08-09 2001-08-09 Hydroxamic acid derivatives
PCT/GB2002/003656 WO2003014101A1 (en) 2001-08-09 2002-08-07 Hydroxamic acid derivatives

Publications (1)

Publication Number Publication Date
MXPA04001212A true MXPA04001212A (es) 2004-07-08

Family

ID=9920067

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001212A MXPA04001212A (es) 2001-08-09 2002-08-07 Derivados de acido hidroxamico.

Country Status (21)

Country Link
US (1) US7015234B2 (es)
EP (1) EP1414812B1 (es)
JP (1) JP2005501090A (es)
KR (1) KR20040035725A (es)
CN (1) CN1275954C (es)
AT (1) ATE318263T1 (es)
BR (1) BR0211780A (es)
CA (1) CA2456291A1 (es)
DE (1) DE60209354T2 (es)
EA (1) EA006877B1 (es)
ES (1) ES2257561T3 (es)
GB (1) GB0119396D0 (es)
HU (1) HUP0401187A2 (es)
IL (1) IL160266A0 (es)
MX (1) MXPA04001212A (es)
NO (1) NO20040551L (es)
NZ (1) NZ531521A (es)
PL (1) PL368228A1 (es)
PT (1) PT1414812E (es)
WO (1) WO2003014101A1 (es)
ZA (1) ZA200401873B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
PL340551A1 (en) * 1997-11-12 2001-02-12 Darwin Discovery Ltd Derivatives of hydroxamic and carboxylic acids exhibiting mmp & tnf inhibitive action
US6187924B1 (en) * 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
US6448250B1 (en) * 1999-02-08 2002-09-10 G. D. Searle & Company Sulfamato hydroxamic acid metalloprotease inhibitor

Also Published As

Publication number Publication date
CA2456291A1 (en) 2003-02-20
IL160266A0 (en) 2004-07-25
JP2005501090A (ja) 2005-01-13
DE60209354T2 (de) 2006-10-19
EP1414812B1 (en) 2006-02-22
PL368228A1 (en) 2005-03-21
ES2257561T3 (es) 2006-08-01
US20040192733A1 (en) 2004-09-30
HUP0401187A2 (hu) 2004-12-28
EA006877B1 (ru) 2006-04-28
NO20040551L (no) 2004-05-10
ZA200401873B (en) 2005-03-08
US7015234B2 (en) 2006-03-21
CN1275954C (zh) 2006-09-20
EA200400287A1 (ru) 2004-06-24
WO2003014101A1 (en) 2003-02-20
NZ531521A (en) 2005-06-24
ATE318263T1 (de) 2006-03-15
CN1568320A (zh) 2005-01-19
EP1414812A1 (en) 2004-05-06
DE60209354D1 (de) 2006-04-27
BR0211780A (pt) 2004-07-27
GB0119396D0 (en) 2001-10-03
PT1414812E (pt) 2006-05-31
KR20040035725A (ko) 2004-04-29

Similar Documents

Publication Publication Date Title
GB9801690D0 (en) Therapeutic agents
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
CA2296604A1 (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
MXPA05011411A (es) 1,4-diazepinas sustituidas y usos de las mismas.
MY136141A (en) Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors
GEP20063931B (en) Uracil substituted phenyl sulfamoyl carboxamides
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1340755A4 (en) AGENT WITH EFFECT AGAINST HELICOBACTER
HUP0102277A2 (hu) 3-Helyzetben heterociklusos csoporttal szubsztituált benzoesavszármazékot tartalmazó herbicid készítmény előállítása és alkalmazása
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
MY128164A (en) Compounds
SE9903290D0 (sv) Novel compounds
MY135375A (en) Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases
MXPA04009421A (es) Compuestos de tiazol-2-ilimina como inhibidores de la pde-7.
TW200505906A (en) Selective mmp-13 inhibitors
MXPA04001212A (es) Derivados de acido hidroxamico.
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
MXPA05006957A (es) Nuevos derivados de fosforamida.
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
EP1325918A4 (en) CARDIOUS CELL APOPTOSIS INHIBITORS AND TREATMENT / PREVENTION OF HEART DISEASES
SE0103325D0 (sv) Novel compounds
TW429147B (en) Pharmaceutical composition for the treatment of CNS disorders
SE9901530D0 (sv) Novel compounds